Literature DB >> 17760805

High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia.

Joanne M Boag1, Alex H Beesley, Martin J Firth, Joseph R Freitas, Jette Ford, David R Brigstock, Nicholas H de Klerk, Ursula R Kees.   

Abstract

In recent years microarrays have been used extensively to characterize gene expression in acute lymphoblastic leukaemia (ALL). Few studies, however, have analysed normal haematopoietic cell populations to identify altered gene expression in ALL. We used oligonucleotide microarrays to compare the gene expression profile of paediatric precursor-B (pre-B) ALL specimens with two control cell populations, normal CD34(+) and CD19(+)IgM(-) cells, to focus on genes linked to leukemogenesis. A set of eight genes was identified with a ninefold higher average expression in ALL specimens compared with control cells. All of these genes were significantly deregulated in an independent cohort of 101 ALL specimens. One gene, connective tissue growth factor (CTGF, also known as CCN2), had exceptionally high expression, which was confirmed in three independent leukaemia studies. Further analysis of CTGF expression in ALL revealed exclusive expression in B-lineage, not T-lineage, ALL. Within B-lineage ALL approximately 75% of specimens were consistently positive for CTGF expression, however, specimens containing the E2A-PBX1 translocation showed low or no expression. Protein studies using Western blot analysis demonstrated the presence of CTGF in ALL cell-conditioned media. These findings indicate that CTGF is secreted by pre-B ALL cells and may play a role in the pathophysiology of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760805     DOI: 10.1111/j.1365-2141.2007.06739.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

Review 1.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

2.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

Review 3.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

4.  Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.

Authors:  Hongbo Lu; Kensuke Kojima; Venkata Lokesh Battula; Borys Korchin; Yuexi Shi; Ye Chen; Suzanne Spong; Deborah A Thomas; Hagop Kantarjian; Richard B Lock; Michael Andreeff; Marina Konopleva
Journal:  Ann Hematol       Date:  2013-10-24       Impact factor: 3.673

5.  Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment.

Authors:  V Lokesh Battula; Ye Chen; Maria da Graca Cabreira; Vivian Ruvolo; Zhiqiang Wang; Wencai Ma; Sergej Konoplev; Elizabeth Shpall; Karen Lyons; Dirk Strunk; Carlos Bueso-Ramos; Richard Eric Davis; Marina Konopleva; Michael Andreeff
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

6.  The role of CCN family genes in haematological malignancies.

Authors:  J E Wells; M Howlett; L C Cheung; Ursula R Kees
Journal:  J Cell Commun Signal       Date:  2015-05-31       Impact factor: 5.782

7.  Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.

Authors:  Keishi Yoshida; Atsushi Fujita; Hidehiko Narazaki; Takeshi Asano; Yasuhiko Itoh
Journal:  Cancer Chemother Pharmacol       Date:  2021-11-26       Impact factor: 3.333

8.  Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.

Authors:  Amy L Samuels; Violet K Peeva; Rachael A Papa; Marin J Firth; Richard W Francis; Alex H Beesley; Richard B Lock; Ursula R Kees
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

9.  Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis.

Authors:  Laurence C Cheung; Deborah H Strickland; Meegan Howlett; Jette Ford; Adrian K Charles; Karen M Lyons; David R Brigstock; Roel Goldschmeding; Catherine H Cole; Warren S Alexander; Ursula R Kees
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

10.  High expression of connective tissue growth factor accelerates dissemination of leukaemia.

Authors:  J E Wells; M Howlett; H M Halse; J Heng; J Ford; L C Cheung; A L Samuels; M Crook; A K Charles; C H Cole; U R Kees
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.